GLP-1 drug shortages, driven by cosmetic and weight loss purposes, result in access disparities among individuals with ...

Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...

In October, the FDA removed Mounjaro and Zepbound—the diabetes and obesity GLP-1 drugs made by Eli Lilly—from the shortage ...

Patients who would benefit from a GLP-1 face significant challenges when it comes to access. Shortages have made it difficult ...

Pharmacies that make customized medications are asking the federal Food and Drug Administration to protect their right to ...

New data shows that government-funded health insurance plans in the United States provide the majority of coverage for ...

Hims & Hers is launching a tracker of GLP-1 shortages to push back against the FDA's recent moves to end compounding copycats ...

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the ...

The FDA updated GLP-1 drug labels to warn of the risk of patients breathing food into their lungs while under anesthesia for ...

has been “resolved” and removed from the FDA’s shortage list, see our prior blog “GLP-1 Drugs: FDA Removes Lilly’s Zepbound® and Mounjaro® (tirzepatide injection) from its Drug ...